Should We Use Dialyzable β-Blockers in Hemodialysis?

Affiliations

¹ Section of Nephrology and Hypertension, First Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² Department of Nephrology, Faculty of Medical Sciences, University of Thessaly, Larissa, Greece.

Editorial

Panagiotis I Georgianos et al. Kidney Med. 2022.

. 2022 Apr 20;4(5):100468.

doi: 10.1016/j.xkme.2022.100468. eCollection 2022 May.

¹ Section of Nephrology and Hypertension, First Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² Department of Nephrology, Faculty of Medical Sciences, University of Thessaly, Larissa, Greece.

No abstract available

References

1. Lea-Henry T.N., Carland J.E., Stocker S.L., Sevastos J., Roberts D.M. Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol. 2018;13(7):1085–1095. - PMC - PubMed
1. Frankenfield D.L., Weinhandl E.D., Powers C.A., Howell B.L., Herzog C.A., St Peter W.L. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D. Am J Kidney Dis. 2012;59(5):670–681. - PubMed
1. Georgianos P.I., Agarwal R. Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. Nat Rev Nephrol. 2016;12(10):636–647. - PubMed
1. Roberts D.M., Sevastos J., Carland J.E., Stocker S.L., Lea-Henry T.N. Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens. Clin J Am Soc Nephrol. 2018;13(8):1254–1263. - PMC - PubMed
1. Tella A., Vang W., Ikeri E., et al. β-blocker use and cardiovascular outcomes in hemodialysis: a systematic review. Kidney Med. 2022 - PMC - PubMed